Oryzon Genomics: Positive Signals From First ALICE Trial Dataset
Edison | Jun 18, 2019 08:34AM ET
On 14 June 2019, Oryzon Genomics SA (BS:ORYe) presented dose-finding data from the Phase II ALICE trial at the 24th Congress of the European Hematology Association (EHA-2019) in Amsterdam. The single-arm, open-label study enrolled newly diagnosed, elderly acute myeloid leukaemia (AML) patients and investigated iadademstat in combination with standard of care chemotherapy drug azacitidine. In addition to dose finding data, initial efficacy was also investigated. Overall, findings in this trial confirm the data seen in the first-in-man Phase I study Oryzon completed in late 2016 and support further investigation of an azacitidine/iadademstat combination in the second efficacy part of the ALICE trial.
Dose-finding data set from Phase II ALICE trial
In this part of the study, which included six AML patients, the combination of iadademstat with azacitidine demonstrated a good safety profile and the recommended dose of 90 µg/m2 was established. This was the initially selected dose, therefore only six patients were needed. Iadademstat produced a clear differentiation effect in leukaemic blasts, ie turn them into normal blood cells (Exhibit 1). 80% of objective responses were observed in five evaluable patients (Exhibit 2). Of these, 75% (3/5) were complete remissions with incomplete haematologic recovery (CRi), while 25% (1/5) were partial remissions. Interestingly, the observed clinical responses appeared rapidly with a median time of 1.5 months.
Our take
Although the study was small and the focus was on establishing the recommended dose, the efficacy findings can be interpreted as showing potential. Notably, impaired differentiation of the leukaemic blasts is at the core of the pathophysiology of the disease. Iadademstat’s ability to induce the differentiation of blasts demonstrates it does what it was designed for. We note that reported overall response rates (ORR) in AML patients treated with azacitidine monotherapy are 25–32% depending on age (DiNardo et al, 2019 ) described a clinical trial (n=145) where AML patients received venetoclax plus azacitidine or decitabine (both chemical analogs of cytidine) and the ORR was 67%. Venetoclax is a novel anticancer drug being developed by AbbVie/Genentech and the ORR of 67% compares well with the initial 80% rate observed in Oryzon’s trial. The second part of the ALICE trial should provide more insight in this regard.
Get The News You Want
Valuation: €430m or €11.0/share
Our valuation remains €430m or €11.0/share and our forecasts are unchanged. The full results from the ALICE trial is the next catalyst in this indication and will prompt us to review our rNPV of the project including the success probability and other target populations as Oryzon indicated that one of the goals of the trial is to understand the broader application of iadademstat in other leukaemias.
Oryzon Genomics is a research client of Edison Investment Research Limited
Business description
Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and SCLC; vafidemstat, its CNS product, is in Phase IIa trials in MS, AD and aggression. Newer asset ORY-3001 is being developed for certain orphan indications.
Next steps
The second part of the ALICE study will enrol up to 18 more patients and focus on the effectiveness of the drug combination. The next set of data should be presented at the ASH meeting in Orlando in December 2019. Iadademstat, as a selective LSD1 inhibitor, has been shown to be effective in preclinical models, including combinations with azacitidine. In addition, Oryzon has already completed a Phase I first-in-man trial, where iadademstat was given as a monotherapy, and demonstrated preliminary initiation report ).
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.